Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
US12071429B2 · kind B2 · utility
0Cited by
20References
27Claims
0Family size
Assignees
Inventors
- Gianni Chessari
- Steven Howard
- Ildiko Maria Buck
- Benjamin David CONS
- Christopher Norbert Johnson
- Rhian Sara HOLVEY
- David Charles Rees
- Jeffrey David ST. DENIS
- Emiliano TAMANINI
- Bernard Thomas Golding
- Ian Robert Hardcastle
- Celine Florence Cano
- Duncan Charles Miller
- Martin Edward Mäntylä Noble
- Roger John Griffin
- James Daniel OSBORNE
- Joanne Peach
- Arwel Lewis
- Kim Louise Hirst
- Benjamin Paul Whittaker
- David Wyn Watson
- Dale Robert Mitchell
Key dates
| Filing date | Feb 1, 2021 |
| Grant date | Aug 27, 2024 |
| Priority date | — |
| Expiry date | Jan 30, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.